Biotech leaders urge Senate to restore FDA’s key functions, cite funding concerns for small companies
More than 200 biotech leaders have penned a letter voicing concerns over the FDA’s capacity after mass layoffs, specifically for small biotechs that depend on investor backing to meet agency standards.
More than 200 biotech leaders have penned a letter voicing concerns over the FDA’s capacity after mass layoffs, specifically for small biotechs that depend on investor backing to meet agency standards.
